Synergistic combination therapy of lung cancer using paclitaxel-and triptolide-coloaded lipid–polymer hybrid nanoparticles

J Liu, H Cheng, L Han, Z Qiang, X Zhang… - Drug design …, 2018 - Taylor & Francis
Purpose Non-small cell lung cancer (NSCLC) accounts for the majority of lung cancer. Lipid–
polymer hybrid nanoparticles (LPNs) combine the advantages of both polymeric …
被引用次数：97 相关文章
[PDF] xarxbio.com

[PDF][PDF] synergistic combination therapy of lung cancer using paclitaxel-and triptolide-coloaded lipid–polymer hybrid nanoparticles

Z Qiang, X Zhang, K Zhao - Drug Design, Development and Therapy, 2018 - xarxbio.com
Purpose: Non-small cell lung cancer (NSCLC) accounts for the majority of lung cancer. Lipid–
polymer hybrid nanoparticles (LPNs) combine the advantages of both polymeric …
[PDF] scienceopen.com

[PDF][PDF] synergistic combination therapy of lung cancer using paclitaxel-and triptolide-coloaded lipid–polymer hybrid nanoparticles

Z Qiang, X Zhang, K Zhao - Drug Design, Development and …, 2018 - scienceopen.com
Purpose: Non-small cell lung cancer (NSCLC) accounts for the majority of lung cancer. Lipid–
polymer hybrid nanoparticles (LPNs) combine the advantages of both polymeric …
[PDF] semanticscholar.org

[PDF][PDF] synergistic combination therapy of lung cancer using paclitaxel-and triptolide-coloaded lipid–polymer hybrid nanoparticles

Z Qiang, X Zhang, K Zhao - Drug Design, Development …, 2018 - pdfs.semanticscholar.org
Purpose: Non-small cell lung cancer (NSCLC) accounts for the majority of lung cancer. Lipid–
polymer hybrid nanoparticles (LPNs) combine the advantages of both polymeric …

Synergistic combination therapy of lung cancer using paclitaxel-and triptolide-coloaded lipid-polymer hybrid nanoparticles

J Liu, H Cheng, L Han, Z Qiang, X Zhang… - Drug Design …, 2018 - hero.epa.gov
Purpose: Non-small cell lung cancer (NSCLC) accounts for the majority of lung cancer. Lipid-
polymer hybrid nanoparticles (LPNs) combine the advantages of both polymeric …
[PDF] archive.org

[PDF][PDF] synergistic combination therapy of lung cancer using paclitaxel-and triptolide-coloaded lipid–polymer hybrid nanoparticles

Z Qiang, X Zhang, K Zhao - Drug Design, Development and …, 2018 - scholar.archive.org
Purpose: Non-small cell lung cancer (NSCLC) accounts for the majority of lung cancer. Lipid–
polymer hybrid nanoparticles (LPNs) combine the advantages of both polymeric …

Synergistic combination therapy of lung cancer using paclitaxel-and triptolide-coloaded lipid-polymer hybrid nanoparticles

J Liu, H Cheng, L Han, Z Qiang… - Drug design …, 2018 - pubmed.ncbi.nlm.nih.gov
Purpose Non-small cell lung cancer (NSCLC) accounts for the majority of lung cancer. Lipid-
polymer hybrid nanoparticles (LPNs) combine the advantages of both polymeric …

Synergistic combination therapy of lung cancer using paclitaxel-and triptolide-coloaded lipid-polymer hybrid nanoparticles.

J Liu, H Cheng, L Han, Z Qiang, X Zhang… - Drug Design …, 2018 - europepmc.org
Purpose Non-small cell lung cancer (NSCLC) accounts for the majority of lung cancer. Lipid-
polymer hybrid nanoparticles (LPNs) combine the advantages of both polymeric …

Synergistic combination therapy of lung cancer using paclitaxel-and triptolide-coloaded lipid-polymer hybrid nanoparticles

J Liu, H Cheng, L Han, Z Qiang, X Zhang… - Drug Design …, 2018 - go.gale.com
Purpose: Non-small cell lung cancer (NSCLC) accounts for the majority of lung cancer. Lipid-
polymer hybrid nanoparticles (LPNs) combine the advantages of both polymeric …

Synergistic combination therapy of lung cancer using paclitaxel-and triptolide-coloaded lipid–polymer hybrid nanoparticles

J Liu, H Cheng, L Han, Z Qiang, X Zhang… - Drug Design …, 2018 - dovepress.com
Purpose: Non-small cell lung cancer (NSCLC) accounts for the majority of lung cancer. Lipid–
polymer hybrid nanoparticles (LPNs) combine the advantages of both polymeric …